Advertisement
"The potentially favorable profile of these compounds was achieved throughthe use of our TRAP(R) computational drug discovery technology," said JamesKeck, Ph.D., Vice President of Biology at Telik. "We are currently conductingactivities necessary to select a potential development candidate."
Advertisement
Preliminary data on Telik's proteasome inhibitor program was presented atthe 2008 annual meeting of the American Association for Cancer Research.
Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused ondiscovering, developing and commercializing novel small molecule drugs totreat serious diseases. The company's most advanced investigational drugcandidates in clinical development are TELINTRA(R), a modified glutathioneanalog for the treatment of cytopenias due to myelodysplastic syndrome orchemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment ofadvanced ovarian cancer and non-small cell lung cancer. Telik's productcandidates were discovered using its proprietary drug discovery technology,TRAP, which enables the rapid and efficient discovery of small molecule drugcandidates. Additional information is available at http://www.telik.com.
This press release contains "forward-looking" statements, includingstatements regarding the potential qualities and capabilities of drugcandidates resulting from the small molecule proteasome inhibitor programdescribed above, including the potential ability of such drug candidates toprevent or stop tumor cell division and starve tumors, and the potentialdevelopment of any drug candidate to treat cancer. These forward-lookingstatements are based upon Telik's current expectations. There are importantfactors that could cause Telik's results to differ materially from thoseindicated by these forward-looking statements. Detailed information regardingfactors that may cause actual results to differ materially from the resultsexpressed or implied by statements in this press release may be found inTelik's periodic filings with the Securities and Exchange Commission,including the factors described in the section entitled "Risk Factors" in itsquarterly report on Form 10-Q for the quarter ended June 30, 2008. Telik doesnot undertake any obligation to update forward-looking statements contained inthis press release.
TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks orregistered trademarks of Telik, Inc.
SOURCE Telik, Inc.
